G protein coupled receptor kinases as therapeutic targets in cardiovascular disease

Circ Res. 2011 Jul 22;109(3):309-19. doi: 10.1161/CIRCRESAHA.110.231233.

Abstract

G protein-coupled receptors (GPCRs) represent the largest family of membrane receptors and are responsible for regulating a wide variety of physiological processes. This is accomplished via ligand binding to GPCRs, activating associated heterotrimeric G proteins and intracellular signaling pathways. G protein-coupled receptor kinases (GRKs), in concert with β-arrestins, classically desensitize receptor signal transduction, thus preventing hyperactivation of GPCR second-messenger cascades. As changes in GRK expression have featured prominently in many cardiovascular pathologies, including heart failure, myocardial infarction, hypertension, and cardiac hypertrophy, GRKs have been intensively studied as potential diagnostic or therapeutic targets. Herein, we review our evolving understanding of the role of GRKs in cardiovascular pathophysiology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / physiopathology
  • G-Protein-Coupled Receptor Kinases / antagonists & inhibitors*
  • G-Protein-Coupled Receptor Kinases / metabolism
  • Humans
  • Protein Kinase Inhibitors / therapeutic use*
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology

Substances

  • Protein Kinase Inhibitors
  • G-Protein-Coupled Receptor Kinases